Significance of APOB/APOA1 Ratio in the Prediction of Calcific Aortic Valve Disease

被引:0
作者
Wang, Yuxing [1 ]
Yu, Ming [1 ]
Yang, Song [1 ]
Mei, Jiajie [1 ]
Liu, Zhenzhu [1 ]
Geng, Zhaohong [1 ]
Xie, Wenli [1 ]
Zhang, Lijiao [1 ]
Wang, Hongyan [1 ]
Niu, Nan [1 ]
Qu, Peng [1 ]
机构
[1] Dalian Med Univ, Hosp 2, Dept Cardiol, Dalian, Liaoning, Peoples R China
关键词
APOB/APOA1; calcific aortic valve disease; prediction model; APOLIPOPROTEIN-A-I; CARDIOVASCULAR-DISEASE; RISK-FACTORS; PLATELET ACTIVATION; BLOOD-PRESSURE; STENOSIS; PROGRESSION; HEART; ROSUVASTATIN; ASSOCIATION;
D O I
10.1155/cdr/5528174
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Calcific aortic valve disease (CAVD) is a prevalent heart valve disease. The ratio of two apolipoproteins with distinct functions, Apolipoprotein B/Apolipoprotein A1 (APOB/APOA1), has been proposed as a novel assessment index for the evaluation of cardiovascular diseases. The aim of this article is to discuss the role of lipid parameters such as APOB/APOA1 in CAVD and the risk factors for CAVD, to develop a predictive model for CAVD, and to evaluate the sensitivity and specificity of this model.Method: Patients who initially presented to the Department of Cardiology of the Second Affiliated Hospital of Dalian Medical University between 1 January 2023 and 31 December 2023 were retrospectively identified and included in the study. Patients were divided into an aortic valve calcification group (111 cases) and a control group (201 cases) based on computed tomography (CT) findings. The clinical data, laboratory examination results, and chest CT images of the patients were collected and analyzed. A variety of statistical methods were used to analyze risk factors for CAVD, to construct a CAVD prediction model, and to assess its sensitivity and specificity.Results: Lipid parameters APOA1, APOB/APOA1, cumulative low-density lipoprotein (LDL) exposure, and non-high-density lipoprotein/high-density lipoprotein (non-HDL/HDL) were significantly associated with aortic valve calcification. Age, history of diabetes, diastolic blood pressure (DBP), APOB/APOA1, Cystatin C (Cys-c), and neutrophil-to-lymphocyte ratio (NLR) are identified as independent risk factors for CAVD, and the combined model achieved an AUC of 0.796 for CAVD prediction, corresponding to a sensitivity of 0.769 and a specificity of 0.755.Conclusion: The lipid parameters APOA1, APOB/APOA1, cumulative LDL exposure, and non-HDL/HDL have been demonstrated to be associated with aortic valve calcification. Furthermore, APOB/APOA1 can be used for the prediction of CAVD, and the combination of APOB/APOA1 with age, history of diabetes, DBP, Cys-c, and NLR has better prediction performance for CAVD.
引用
收藏
页数:14
相关论文
共 70 条
[1]   Cardiovascular Disease Risk Assessment and Prevention Current Guidelines and Limitations [J].
Alagona, Peter, Jr. ;
Ahmad, Tariq Ali .
MEDICAL CLINICS OF NORTH AMERICA, 2015, 99 (04) :711-+
[2]   Risk factors for myocardial infarction in women and men: insights from the INTERHEART study [J].
Anand, Sonia S. ;
Islam, Shofiqul ;
Rosengren, Annika ;
Franzosi, Maria Grazia ;
Steyn, Krisela ;
Yusufali, Afzal Hussein ;
Keltai, Matyas ;
Diaz, Rafael ;
Rangarajan, Sumathy ;
Yusuf, Salim .
EUROPEAN HEART JOURNAL, 2008, 29 (07) :932-940
[3]   Cystatin C: An Emerging Biomarker in Cardiovascular Disease [J].
Angelidis, Christos ;
Deftereos, Spyridon ;
Giannopoulos, Georgios ;
Anatoliotakis, Nikolaos ;
Bouras, Georgios ;
Hatzis, Georgios ;
Panagopoulou, Vasiliki ;
Pyrgakis, Vlasios ;
Cleman, Michael W. .
CURRENT TOPICS IN MEDICINAL CHEMISTRY, 2013, 13 (02) :164-179
[4]  
[Anonymous], Value of APOB/APOA1 Ratio in Prediction of Calcific Aortic Valve Disease in Reference Section in the Final Updated Main Manuscript Word Document
[5]   Apolipoprotein B100 danger-associated signal 1 (ApoBDS-1) triggers platelet activation and boosts platelet-leukocyte proinflammatory responses [J].
Assinger, Alice ;
Wang, Yajuan ;
Butler, Lynn M. ;
Hansson, Goran K. ;
Yan, Zhong-qun ;
Soderberg-Naucler, Cecilia ;
Ketelhuth, Daniel F. J. .
THROMBOSIS AND HAEMOSTASIS, 2014, 112 (02) :332-341
[6]   Calcific Aortic Valve Stenosis and Atherosclerotic Calcification [J].
Barros de Oliveira Sa, Michel Pompeu ;
Cavalcanti, Luiz Rafael P. ;
Perazzo, Alvaro M. ;
Gomes, Rafael A. F. ;
Clavel, Marie-Annick ;
Pibarot, Philippe ;
Biondi-Zoccai, Giuseppe ;
Zhigalov, Konstantin ;
Weymann, Alexander ;
Ruhparwar, Arjang ;
Lima, Ricardo Carvalho .
CURRENT ATHEROSCLEROSIS REPORTS, 2020, 22 (02)
[7]   Total cholesterol/HDL-C ratio versus non-HDL-C as predictors for ischemic heart disease: a 17-year follow-up study of women in southern Sweden [J].
Calling, Susanna ;
Johansson, Sven-Erik ;
Wolff, Moa ;
Sundquist, Jan ;
Sundquist, Kristina .
BMC CARDIOVASCULAR DISORDERS, 2021, 21 (01)
[8]   Aortic stenosis: insights on pathogenesis and clinical implications [J].
Carita, Patrizia ;
Coppola, Giuseppe ;
Novo, Giuseppina ;
Caccamo, Giuseppa ;
Guglielmo, Marco ;
Balasus, Fabio ;
Novo, Salvatore ;
Castrovinci, Sebastiano ;
Moscarelli, Marco ;
Fattouch, Khalil ;
Corrado, Egle .
JOURNAL OF GERIATRIC CARDIOLOGY, 2016, 13 (06) :489-498
[9]   Effect of Lipid Lowering With Rosuvastatin on Progression of Aortic Stenosis Results of the Aortic Stenosis Progression Observation: Measuring Effects of Rosuvastatin (ASTRONOMER) Trial [J].
Chan, Kwan Leung ;
Teo, Koon ;
Dumesnil, Jean G. ;
Ni, Andy ;
Tam, James .
CIRCULATION, 2010, 121 (02) :306-U247
[10]  
Chen Y. M., 2013, Medical Recapitulate, V19, P3395, DOI [10.3969/j.issn.1006-2084.2013.18.045, DOI 10.3969/J.ISSN.1006-2084.2013.18.045]